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ABSTRACT: Functional protein−gold nanoparticle (AuNP) conjugates have a wide variety of applications including
biosensing and drug delivery. Correct protein orientation, which is important to maintain functionality on the nanoparticle
surface, can be difficult to achieve in practice, and dedicated protein scaffolds have been used on planar gold surfaces to drive
the self-assembly of oriented protein arrays. Here we use the transmembrane domain of Escherichia coli outer membrane protein
A (OmpATM) to create protein−AuNP conjugates. The addition of a single cysteine residue into a periplasmic loop, to create
cysOmpATM, drives oriented assembly and increased equilibrium binding. As the protein surface concentration increases, the
sulfur−gold bond in cysOmpATM creates a more densely populated AuNP surface than the poorly organized wtOmpATM layer.
The functionalization of AuNP improved both their stability and homogeneity. This was further exploited using multidomain
protein chimeras, based on cysOmpATM, which were shown to form ordered protein arrays with their functional domains
displayed away from the AuNP surface. A fusion with protein G was shown to specifically bind antibodies via their Fc region.
Next, an in vitro selected single chain antibody (scFv)-cysOmpATM fusion protein, bound to AuNP, detected influenza A
nucleoprotein, a widely used antigen in diagnostic assays. Finally, using the same scFv-cysOmpATM−AuNP conjugates, a
prototype lateral flow assay for influenza demonstrated the utility of fully recombinant self-assembling sensor layers. By
simultaneously removing the need for both animal antibodies and a separate immobilization procedure, this technology could
greatly simplify the development of a range of in vitro diagnostics.
KEYWORDS: gold nanoparticles, self-assembly, outer membrane proteins, single chain variable fragment, LSPR, lateral flow assay,
biosensing
■ INTRODUCTION
The generation of functional AuNP-protein conjugates is of
great interest and importance for many bioscience applications,
particularly diagnostics and therapeutics.1,2 AuNPs are an
attractive vehicle for biomolecules as they can be made in well-
defined sizes,3 are biocompatible,4 and exhibit unique optical
properties that provide an intrinsic ability to sense changes in
the local environment5 and have also been utilized for
therapeutic purposes.6−8 Protein, i.e., mostly antibody,
conjugation is generally used to bestow biological functionality
to the AuNP surface, such as targeting of a particular protein or
antigen of interest9,10 or carrying out therapeutic processes,
including gene editing.11,12 Numerous protein attachment
strategies have been developed, usually via chemically modified
linker molecules that are assembled on the AuNP surface
through terminal thiol groups.13 These linker chemistries can
be quite widely applicable, such as coupling to amines or
hydrazide coupling of antibody glycans. Furthermore, it has
been shown that more directed coupling, providing orienta-
tional control, improves functionality of the protein−nano-
particle conjugates.9,10 Control over antibody orientation has
been shown to enhance antigen binding when immobilized on
planar surfaces.14 Previously, it has been shown that outer
membrane β-barrel proteins from Escherichia coli can be
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engineered to self-assemble into oriented monolayers on
planar gold surfaces. An upright orientation was driven by both
the addition of a single cysteine residue into a periplasmic turn
and coassembly with membrane mimicking thioAlkylPEG
molecules.15,16 The transmembrane domain of E. coli outer
membrane protein A (OmpATM) can be used as such a protein
engineering scaffold protein when circularly permuted to
enable modification of its extracellular loops.17 This allows
heterologous functional domains, such as antibody binding
domains from protein A and protein G,18,19 to be fused to
OmpATM and displayed away from the surface. The utility of
such protein arrays on planar gold surfaces for biological
sensing has been previously presented.20 AuNP−protein
conjugates are widely used in diagnostic assays, particularly
for lateral flow tests, where they are used to detect many
different antigens, e.g., hormones and viral proteins.21 While
protein binding to AuNPs has been extensively researched,
most studies have focused on the stoichiometry and
thermodynamics of globular model proteins such as serum
albumins and ubiquitin.22−25 There are fewer examples of
Scheme 1. Assembly of the Modular Protein System on the AuNP Surface and Binding of an Antigen in Solution
Figure 1. Binding and stability of wtOmpATM (red box) and cysOmpATM (●) to 20 nm AuNPs. AuNPs at an OD525nm = 1 were mixed with
protein at concentrations between 0.016 and 0.8 μM before overnight incubation at room temperature. (A) Example spectra of AuNPs before
(black line) and after (red line) overnight incubation with 0.8 μM cysOmpATM showing the significant shift in the LSPR peak. (B) Shift in the
LSPR barycentric mean wavelength (Δλm) after overnight equilibration. (C) Fluorescence spectroscopy results showing the average number of
proteins bound to each AuNP with increasing protein concentration. The amount of protein binding was calculated by the reduction in soluble
protein fluorescence signal caused by incubation with AuNPs and their subsequent removal along with bound protein. (D) Change in the LSPR
Δλm of wtOmpATM and cysOmpATM−AuNP conjugates (ΔΔλm) when challenged with increasing concentrations of NaBH4. Error bars represent
the standard error of the mean based upon N = 3.
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control over protein orientation, with changes in AuNP surface
charge26 and site-directed insertion of cysteine residues27 being
shown to influence α-synuclein and E. coli PPase orientation
on the AuNP surface, respectively. Here we present the self-
assembly of engineered OmpATM proteins on the surface of 20
nm AuNPs (Scheme 1). Protein binding could be sensitively
monitored by observing changes in the localized surface
plasmon resonance (LSPR) peak, and the protein layer
structure was investigated by dynamic light scattering (DLS).
Furthermore, we introduce chimeric, single chain antibody-
OmpATM proteins as a simple method to functionalize AuNP
conjugates to detect a clinical antigen, influenza A
nucleoprotein (FluA NP). NP is the preferred target for
diagnostic assays due to its highly conserved nature and type
specificity for type A and B influenza.20,28
■ RESULTS AND DISCUSSION
Cysteine Mediated Binding and Assembly of Om-
pATM. Initially we investigated the effect of a single cysteine
residue, inserted into a periplasmic turn of OmpATM, on the
binding of detergent solubilized OmpATM to the surface of
AuNPs. We present data exclusively for 20 nm diameter
commercial, citrate stabilized AuNPs, but we have also
successfully used the 10 nm version and even homemade
AuNPs prepared by precipitation from Au2Cl6. The presence
of a single cysteine per protein was confirmed by DNA
sequencing of the cysOmpATM gene and the cysteine reactivity
after TCEP treatment has been confirmed previously.17
Protein binding was measured by the shift in the barycentric
mean wavelength (Δλm) of the LSPR absorption peak. Higher
equilibrium binding was observed for the cysOmpATM mutant
than for the wild type protein (wtOmpATM), with an increase
in the Δλm of 0.93 nm (Figure 1A). The increased binding was
also observed by fluorescence spectroscopy experiments which
recorded the reduction in concentration of free protein (Figure
1B). To confirm the formation of a sulfur−gold bond, the
stabilities of the WT and cysOmpATM protein−AuNP
conjugates were probed by challenging the particles with
borohydride ions (BH4
−), which have a high affinity for the
nanoparticle surface.29 This revealed a significant increase in
the stability of the conjugated particles when the cysteine
residue was present (Figure 1C).
A stark difference between the two particle types was
revealed by agarose gel electrophoresis where the cysOm-
pATM−AuNP conjugates migrate faster than the wild type−
AuNP conjugates, indicating that they had an increased net
negative charge (OmpATM has an estimated charge of −3.6 at
pH 8) (Figure 2A). Characterization of these protein−AuNP
conjugates by DLS showed that the diameters of the
wtOmpATM and cysOmpATM particles were remarkably
similar; however the latter sample had a greater LSPR λm
shift indicating greater protein binding (Figure 2B and Figure
2C). The assembly for this experiment was carried out at a 10
times higher overall concentration of both protein and AuNP
compared to Figure 1, and while the LSPR shifts for
wtOmpATM increase from 1.4 to 2.0 nm, the cysOmpATM
Figure 2. Characterization of AuNPs (preconjugated with wild type and cysOmpATM) before and after overnight thioAlkylPEG filler incubation. 20
nm AuNPs at OD525nm = 10 were incubated with 8 μM of either protein for 30 min, followed by coassembly with filler by mixing the protein−
AuNP conjugates with 8 μM filler and incubating overnight. (A) 0.5% agarose gel of wtOmpATM particles before (1) and after filler addition (2)
and cysOmpATM particles before (3) and after (4) filler (F) addition. Corresponding LSPR absorbance peak barycentric mean wavelength Δλm (B)
and change in hydrodynamic radius (ΔDHyd) measured by DLS (C) data (where ΔDHyd = 0 corresponds to bare particles) for the same protein−
AuNP conjugate samples used in (A). Error bars represent the standard error of the mean based upon three measurements.
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values are 2.4 and 2.1, respectively, confirming the apparent
surface saturation observed at 0.8 μM cysOmpATM and the less
specific binding of the WT protein. Infilling of the nanoparticle
surface with an uncharged lipid mimicking molecule, 1-
mercaptoundecyl-11 hexa(ethylene glycol) (filler), increased
the size of both wild type and cysOmpATM particles, as seen by
DLS, and retarded the electrophoretic migration of the
particles (Figure 2A and Figure 2C). The effect of filler
addition on both the size of the particles and the increase in
the Δλm was much more pronounced for the cysOmpATM
particles. These results suggest that insertion of the cysteine
residue plays a role in both protein binding and organized
assembly of OmpATM on the nanoparticle surface. Interest-
ingly, the binding kinetics of the wild type and cysOmpATM
proteins were strikingly similar, with pseudo-second-order rate
constants of 14.76 ± 1.12 and 14.86 ± 1.09 × 10−3 s−1 nm−1
respectively (Supporting Information). This would suggest that
electrostatic interactions dominate the early stages of protein
binding, i.e., in the seconds to minutes range, followed by
reorganization of the protein layer to maximize the number of
favorable interactions. Protein binding to AuNPs has been
shown to obey equilibrium dynamics;23,25 therefore the
formation of a thermodynamically stable thiol−gold bond
between the protein and AuNP would shift the binding
equilibrium toward associated and oriented protein. Outer
membrane β-barrels consist of a hydrophobic core region,
which normally resides in the lipid membrane, and hydrophilic
loops at their periplasmic and extracellular ends. A standing
orientation, driven by the location of the cysteine in a
periplasmic loop, as shown by neutron scattering experiments
on planar surfaces,17 maximizes favorable hydrophobic
interactions with filler molecules and neighboring proteins
while minimizing the surface footprint of bound proteins, thus
increasing the maximum adsorption capacity of the nano-
particle surface. A more organized cysOmpATM array on the
AuNP surface would explain the increase in the apparent
Figure 3. Characterization of GGzOmpATM−AuNP conjugates. (A) Cartoon of GGzOmpATM which consists of tandem B-domains (red) from
protein G and a single Z domain from protein A (magenta) fused to the N-terminus of a circularly permuted OmpATM domain (green). (B) 0.5%
agarose gel comparing cysOmpATM coated particles, before (1) and after (2) filler addition, and GGzOmpATM coated particles, before (3) and after
(4) filler addition. (C) Corresponding DLS data for the agarose gel samples showing the increase in the hydrodynamic diameter (ΔDHyd) of the
particles (where ΔDHyd = 0 corresponds to bare particles). (D) Representative negative stain TEM images of bare AuNPs (1) and GGzOmpATM +
filler conjugated AuNPs (2 and 3). Scale bar = 25 nm. The protein coated AuNPs were prepared for TEM by excising the agarose gel band from
lane 4 in (B) and extracting overnight in Nanopure H2O. (E) AUC analysis of commercial 20 nm AuNPs before and after conjugation with
GGzOmpATM and filler. Both size (top) and size-and-shape (bottom) distributions of the particles are shown. The friction ratio corresponds to the
symmetry of the particle with a value of 1 indicating a spherical particle.
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protein binding and also the increased filler binding observed
compared to a wtOmpATM array with poorly oriented proteins
in many different conformations. The high wtOmpATM
binding is most likely due to exposed lysine resides, which
have been shown to mediate binding to AuNP;30 in particular,
residues K73 and R102 form a positively charged surface at the
extracellular end of the barrel. The N-terminal 6xHis-tag may
also play a role in AuNP binding.31 The protein binding
behavior observed in this study is consistent with a protein
binding model proposed by Wang et al., where initial
association is dynamic and reversible, followed by reorganiza-
tion of the protein layer to maximize the available AuNP
surface and, finally, irreversible binding of the protein which is
accelerated here by the exposed cysteine residue.25
Surface Assembly of Antibody Capture Domains. To
test the utility of cysOmpATM−AuNP conjugates as a
diagnostic tool, a multidomain version termed GGzOmpATM
was used. This protein combines tandem B-domains from
protein G (GG)19 and a Z-domain from protein A (z)18 bound
to the N-terminus of a circularly permuted OmpA trans-
membrane domain (OmpATM)
20 and has a total length of
approximately 135 Å when standing on a gold surface20
(Figure 3 A). Both B- and Z-domains bind to the constant
regions of immunoglobulin G (IgG) enabling oriented
presentation of antibodies on surfaces so that their binding
sites are exposed. As expected, gel electrophoresis and DLS
measurements showed a greater increase in particle size on
addition of GGzOmpATM when compared with cysOmpATM
(Figure 3B and Figure 3C). Negative stained transmission
electron microscopy images of GGzOmpATM−AuNP con-
jugates also revealed material bound to the surface that was not
visible on untreated particles (Figure 3D). These features are
too large to be individual GGzOmpATM proteins and may be
groups of closely associated proteins since at around 11 nm in
length they are consistent with the height of GGzOmpATM.
Further analysis of GGzOmpATM−AuNP conjugates was
carried out using sedimentation velocity analytical ultra-
centrifugation. One-dimensional sedimentation coefficient,
c(s), distribution analysis32 showed broad single peaks for
each sample (Figure 3E, top panel). The c(s) distributions of
the protein coated AuNPs were clearly affected by changes in
their size and density when compared with the untreated
AuNPs. More in-depth analysis using a two-dimensional “size
and shape” distribution,33−35 c(s,f/f 0), demonstrated a higher
fraction of aggregated, asymmetrical species (with a friction
ratio significantly above 1) before addition of the filler
molecule on to the AuNP surface (Figure 3E, bottom
panel). This suggests that incorporation of filler molecules
into the GGzOmpATM layer results in a more ordered protein-
filler array. The resulting particles were more spherical in shape
and had a lower level of inhomogeneity when compared with
AuNPs coated in just GGzOmpATM (more details in the
Supporting Information).
Figure 4. Assembly of GGzOmpATM arrays on 20 nm AuNPs. (A) Hydrodynamic diameter (Dhyd) of AuNPs measured by DLS showing changes in
Dhyd after sequential addition of GGzOmpATM, thioAlkylPEG filler (F), and a monoclonal antibody (mAb). (B) DLS data comparing change in the
Dhyd of GGzOmpATM coated particles with wtOmpATM and cysOmpATM control particles after incubation with a mAb (where ΔDHyd = 0
corresponds to the value from protein coated particles). (C) Schematic representation of the protein layers after each step with the indicated layer
thicknesses calculated from the changes in the Dhyd reported in (A) and (B). Error bars represent the standard error of the mean based upon N = 3.
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Assembly of GGzOmpATM−AuNP and subsequent binding
of a monoclonal antibody were followed by DLS (Figure 4A
and Figure 4C). This showed a surface layer thickness of 10.1
± 0.53 and 12.13 ± 0.68 nm after addition of GGzOmpATM
and the thioAlkylPEG filler, respectively, confirming that
infilling of the surface may encourage a more perpendicular
protein orientation. This observation is consistent with
previous AFM and neutron reflection studies of engineered
OmpATM arrays on planar gold surfaces
16,17 which showed an
increase in orientation and stability after filler assembly. The
protein layer thickness and antibody binding function were
thus indicative of ordered protein assembly where the antibody
binding domains are displayed away from the particle surface.20
Incubation with a mAb formed a combined thickness of 19.26
± 2.04 nm protein on the AuNP surface, confirming that the
B-domains were free to bind antibody. The increase in
standard error from ±0.68 to ±2.04 nm in the DLS
measurements after mAb binding was suggestive of a less
homogeneous population of particles, possibly due to differing
amounts of mAb bound. Antibody binding was specific to
GGzOmpATM coated AuNPs with wild type and cysOmpATM
particles showing low levels of nonspecific binding (Figure
4B).
Surface Assembly of Antibody Domains for Influenza
Detection. The most common application of conjugated
AuNPs is in diagnostic tests where they are used to detect a
number of different antigens such as proteins and DNA.36
Therefore, the ability of the modular OmpATM system,
assembled on AuNPs, to detect a clinical antigen was tested.
For this we used a different OmpATM fusion protein which
contained at its N-terminus an antigen binding domain derived
from an antibody. Since the antigen binding or complemen-
tarity-determining regions (CDRs) of antibodies consist of two
separate proteins, engineered versions called single chain
variable fragments (scFv) have been developed which combine
the recognition domains of immunoglobulins into a single
polypeptide chain. These can be derived from known
antibodies, or novel functions can be developed using
combinatorial selection procedures to select the scFv of choice
from a random library.37 This protein (scFvOmpATM)
consisted of a bespoke single chain variable fragment (scFv
domain), selected to bind influenza A nucleoprotein (FluA
NP) using a bacterial retained display platform and affinity
selection techniques,38 fused to the N-terminus of circularly
permuted cysOmpATM via an α-helical linker domain. This
engineered protein eliminates the need for both animal derived
antibodies and immobilization chemistries, allowing a highly
selective AuNP surface to be manufactured using a single
recombinant protein easily manufactured by bacterial
fermentation. A second protein (*OmpATM), which consisted
of just the cysOmpATM and α helical linker domains, was used
as a negative control (Figure 5A and Figure 5B). Binding of
recombinant FluA NP to scFvOmpATM conjugated particles
was observed by UV−vis spectroscopy as a red shift in the
LSPR peak and DLS as a large increase in the particle size
(Figure 5C and Figure 5D). TEM images of scFvOmpATM
particles after incubation with FluA NP revealed large objects
bound to the surface of the particles that were not present
before antigen addition (Figure 5E and Figure 5F). These are
larger than expected for NP; however the monomeric species
Figure 5. Detection of recombinant influenza A nucleoprotein (FluA NP) with scFvOmpATM conjugated 20 nm AuNPs. (A, C) UV−vis spectra of
the assembly and subsequent incubation with FluA NP of the *OmpATM control (helical linker) and scFvOmpATM (linker plus variable heavy VH
and variable VL light chains of IgG antibody) proteins on AuNPs. (B, D) Particle size distribution anaylsis of *OmpATM and scFvOmpATM
conjugated particles before and after incubation with FluA NP. Representative negative stain TEM images of scFvOmpATM conjugated AuNPs
before (E) and after (F) incubation with FluA NP. Bound FluA NP is indicated by the black arrows, and the scale bar is 25 nm. (G) Lateral flow
assay which used α-FluA NP and α-human IgG antibodies, as the capture and control lines, respectively. Strips 1−4 correspond to scFvOmpATM
particles incubated with between 5000 and 500 ng/mL of FluA NP, respectively. Strips 5 and 6 compare scFvOmpATM particles incubated with
5000 ng/mL FluA NP and RSV NP, respectively. Strip 7 shows *OmpATM conjugated particles incubated with 5000 ng/mL FluA NP. All protein−
AuNP conjugates were made with both protein and thioAlkylPEG filler.
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exists in equilibrium with trimers39 which at 150 kDa
approximate to the structures seen here. This flu NP
quaternary structure also explains both the cross-linking of
AuNP by the flu antigen observed in EM (Figure 5 F) and, by
forming multi AuNP-FluA NP complexes via multivalent
interactions, the strong binding response seen by spectroscopy
and DLS. This effect has also been exploited in AuNP LSPR
based assays of intact flu virus where binding to the
hemagglutinin proteins on the viral surface brings many
AuNP into close proximity.40 Here, samples of the complexes
were observed by TEM with FluA NP apparently bridging
between different scFvOmpATM−AuNP conjugates (Figure
5F). Detection of FluA NP was thus robust and specific.
Control particles conjugated with *OmpATM, the negative
control protein, did not show any FluA NP binding by either
UV−vis spectroscopy or DLS. Finally, FluA NP binding to
scFvOmpATM−AuNP conjugates was tested using a lateral
flow assay (LFA). LFAs are widely used in diagnostics and
comprise a porous membrane, commonly nitrocellulose, to
which antibodies are immobilized in defined lines.21 Samples
suspected of containing the antigen are mixed with visible
particles, usually AuNPs or latex beads that have been
conjugated with a second antibody, which recognizes a
secondary site on the antigen. This solution is allowed to
flow along the strip, with any bound antigen forming a cross-
link between the particle and the immobilized antibody,
leading to the formation of a characteristic colored line. A
second antibody line on the strip acts as a control, binding to
the antibody on the particle surface. A prototype lateral flow
assay which used α-FluA NP and α-human IgG antibodies, as
the capture and control lines respectively, could detect a
minimum of 500 ng/mL FluA NP when incubated with
scFvOmpATM coated particles (Figure 5G). This is comparable
sensitivity to commercially available anti-NP antibodies used in
diagnostic assays.41 Detection was specific to FluA NP with no
capture line observed for scFvOmpATM particles incubated
with recombinant respiratory syncytial virus nucleoprotein
(RSV NP) (Figure 5G). Detection was also accurate and
discriminatory since all samples containing FluA NP were
positive and no capture or control binding was observed for
AuNPs conjugated with the *OmpATM control protein after
incubation with FluA NP (Figure 5G). Comparison of the
detection limits with other methods is somewhat difficult as
they are not always directly comparable. It is also difficult to
find primary data for the detection limits of commercial LFAs.
The detection limit presented here is comparable to a lateral
flow assay using silica nanoparticles42 and a double antibody
sandwich enzyme-linked immunosorbent ELISA assay.43
However, more complex detection methods, such as two-
photon fluorescence excitation, have been able to detect
nucleoprotein concentrations down to 50 ng/mL.44 The
experimental conditions used here, while not using patient
samples, are comparable to the clinical situation where the
tests use diluted washes of nasal swabs. These samples are free
of the complications of blood samples and, compared to tests
for other biomarkers, contain relatively large amounts of shed
virions and viral proteins.
■ CONCLUSION
The work presented here describes the simple creation of gold
nanoparticles decorated with functional protein domains
suitable for diagnostic applications. The addition of a single
cysteine residue in a periplasmic loop of OmpATM plays an
important role in its assembly on the surface of AuNPs.
Although significant amounts of WT protein bind to AuNP,
the addition of the cys residue leads to larger amounts of
bound protein, greater stability (Figure 1), more efficient
assembly of the membrane mimicking thioAlkylPEG layer
(Figure 2), and improved protein orientation, consistent with
previous studies.15−17,20 We then used two different
engineered multidomain OmpATM protein chimeras. GGzOm-
pATM, which contains antibody binding domains, was shown to
form ordered protein arrays on AuNPs with the functional G-
domains displayed away from the surface and able to display
monoclonal IgG antibodies. Next we fused a single domain
antibody, which recognizes the influenza antigen FluA NP, to
OmpATM (scFv-OmpATM). FluA NP is an important
diagnostic antigen used in the detection of influenza infections.
Nanoparticles decorated with anti-FluA NP scFv-OmpATM
were used to detect FluA NP using UV−vis spectroscopy,
dynamic light scattering, and electron microscopy. Further-
more, it was used in a lateral flow assay (Figure 5) as proof of
concept for using self-assembled engineered membrane
proteins in a clinically relevant diagnostic test. By fusing
recombinant single chain antibodies with a self-assembling
scaffold protein, this approach removes the need for complex
and inefficient conjugation of animal derived antibodies. It has
the scope to detect a wide variety of antigens with antibody-
like specificity while being economically produced on a large
scale by bacterial fermentation. Additional applications could
include gold labeling of cellular or engineered (FLAG)
antigens in electron microscopy.
■ MATERIALS AND METHODS
Materials. Gold nanoparticles were purchased from BBI Solutions
(Cardiff, U.K.). Antibodies were purchased from HyTest (Turku,
Finland) and Abcam (Cambridge, U.K.). Molecular biology and
protein purification materials were purchased from Invitrogen,
Generon, and GE Healthcare (U.K.). All other materials were
purchased from Sigma-Aldrich unless otherwise stated.
Protein Production and Purification. wtOmpATM and
cysOmpATM were expressed, purified, and refolded from inclusion
bodies as described previously for OmpAZ.15 GGzOmpATM was
expressed, purified, and refolded as described previously.20
scFvOmpATM was expressed, purified, and refolded as described for
GGzOmpATM. The bespoke scFv domain was purchased from Affinity
Bio (Scoresby, Australia). *OmpATM was also expressed, purified, and
refolded as described for GGzOmpATM. Recombinant influenza A
nucleoprotein expression and purification were carried out as
described previously.20 Recombinant respiratory syncytial virus
nucleoprotein expression and purification were carried out as for
influenza A nucleoprotein.
Equilibrium Binding Measurements. wtOmpATM and cysOm-
pATM were buffer exchanged into DDM buffer (0.5% w/v n-dodecyl
β-D-maltoside, 10 mM Tris-HCl, pH 8) using a PD10 desalting
column (GE Healthcare). The resulting protein solution was
incubated in 5 mM TCEP (tris(2-carboxyethyl)phosphine) for 30
min before use. 20 nm AuNPs at OD525nm = 1 were mixed with
protein at concentrations between 0.016 and 0.8 μM before overnight
incubation at room temperature. UV−vis spectra were acquired with a
Cary 4E spectrophotometer between 400 and 800 nm. The
barycentric mean wavelength (λm) was calculated between 500 and
600 nm using the following equation:45
I
I
( )
( )m
λ λ λ
λ
= ∑
∑
where I(λ) is the absorbance at wavelength λ. The shift (Δλm) was
calculated as the difference from the λm of nonfunctionalized AuNPs.
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Fluorescence Spectroscopy. Overnight assembly of wtOmpATM
and cysOmpATM−AuNP conjugates was carried out as for the
equilibrium binding experiments with protein concentrations between
0.08 and 0.8 μM. Before carrying out fluorescence measurements of
protein concentration, the protein−AuNP conjugates were removed
by centrifugation at 20 000g for 10 min. Protein binding was
calculated by measuring the residual protein concentration using the
intensity of the tryptophan fluorescence of the supernatant.
Fluorescence spectra were acquired using a Cary Eclipse fluorescence
spectrophotometer using 5 mm path length quartz cuvettes (Hellma
111.057). Excitation was at 280 nm and emission scanned between
300 and 450 nm. Total fluorescence was calculated by integrating the
intensities between 300 and 400 nm for each sample and the protein
concentration calculated from a calibration curve made using protein
standards between 0.0125 and 1 μM.
Protein−AuNP Conjugate Stability. Overnight preparation of
wtOmpATM and cysOmpATM−AuNP conjugates was carried out as
for the equilibrium binding experiments with a protein concentration
of 0.8 μM. Protein−AuNP conjugates at OD525nm = 1 were mixed
with NaBH4 at concentrations between 0.05 and 1.5 mM before
incubating at room temperature for 3 h. UV−vis spectra were
acquired with the Cary 4E spectrophotometer for the protein−AuNP
conjugates before and after NaBH4 addition. Stability was measured
as the ratio of the shift in the λm before and after NaBH4 addition.
Agarose Gel Electrophoresis. Protein−AuNP conjugates were
made by mixing 20 nm AuNPs at OD525nm = 10 with 8 μM protein
before overnight incubation. Coassembly of the 1-mercaptoundecyl-
11-hexa(ethylene glycol) filler molecule was carried out 30 min after
incubation with the protein by mixing the protein−AuNP conjugates
with 8 μM filler and incubating overnight. Electrophoresis was carried
out using 1% agarose gels made with TB buffer (90 mM Tris-HCl, 90
mM boric acid) and run in TB buffer supplemented with 0.025%
Tween 20. 20 μL of AuNP sample was mixed with 5 μL of loading
buffer (TB buffer supplemented with 30% w/v glycerol and 0.05%
Tween 20) before loading on the gel and running for 70 min at 100 V
in an ice bath. Gels were imaged immediately using a Bio-Rad Gel
Doc XR+.
Transmission Electron Microscopy. GGzOmpATM−AuNP
conjugates were excised from agarose gel bands and extracted
overnight into Nanopure water. Samples were deposited on to 200
mesh, carbon coated, glow discharged grids using the single droplet
method.46 Negative staining was carried out with a 2% uranyl acetate
solution. All samples were imaged using a Philips CM100 TEM with a
CompuStage. The resulting images were processed using the ImageJ
software (NIH).
Dynamic Light Scattering. DLS measurements were carried out
in a 45 μL cuvette (Hellma) with a Malvern Zetasizer Nano S.
Residual protein was removed by centrifugation of the protein−AuNP
conjugates at 16 900g and resuspension in Nanopure water. For
antibody binding experiments, protein conjugated particles were
mixed with 1 μM monoclonal antivinculin antibody and incubated for
10 min before centrifugation at 16 900g and resuspension in
Nanopure water.
FluA NP Binding Experiments. scFvOmpATM−AuNP conju-
gates were made with protein and filler concentrations of 0.8 μM
using the same method as for cysOmpATM. Residual protein was
removed by centrifugation and resuspension in Nanopure water. The
resulting scFvOmpATM−AuNP conjugates, at OD525nm = 1, were
mixed with 150 nM of FluA NP and incubated for 10 min before
residual protein was removed by centrifugation and resuspension in
Nanopure water. UV−vis spectroscopy, DLS, and TEM were then
carried out on the protein−AuNP conjugates before and after FluA
NP incubation.
Analytical Ultracentrifugation (AUC). Sedimentation velocity
(SV) experiments were carried out with a Beckman Coulter Optima
XL-I analytical ultracentrifuge (Palo Alto, CA, USA) using both
absorbance at 530 nm and interference optics at a rotation speed of
5000 rpm and experimental temperature of 20 °C. The AuNPs were
diluted in water to a final concentration of OD530nm = 1.5 with a path
length of 1 cm. A sample volume of 400 μL was used. Sedimentation
velocity profiles were analyzed using both 1D size-distribution
c(s)32,32 and 2D distribution c(s,f/f 0)
33,33 models implemented in
the program SEDFIT.47,44 Each peak on the distribution plot was
integrated in order to obtain the weight-averaged values for
sedimentation coefficient. In brief, sedimentation of the material is
described by the Svedberg equation as follows:48,45
M
sRT
D v(1 )particle solventρ
=
− ̅
where M is the particle’s molecular mass, s is its sedimentation
coefficient, D is the diffusion coefficient, v̅particle is the partial specific
volume of the sedimenting particle, ρsolvent is the density of the
solvent, T is the absolute temperature, and R is the ideal gas constant.
The partial specific volume can be represented in terms of the
particle’s density, ρparticle, as
v 1/ particleρ̅ =
The density of the particle can, in turn, be expressed as a function of
its hydrodynamic radius, Rh, and sedimentation coefficient, s,
by35,49,35,46
s
R
18
(2 )particle solvent
solvent
h
2ρ ρ
η
= +
where ρsolvent is the density of the solvent and ηsolvent is its viscosity.
Lateral Flow. Lateral flow strips were made from nitrocellulose
membrane (4 cm × 30 cm) with capture and control antibody lines
deposited by hand using a pipet tip at 0.5 mg/mL in binding buffer
(10 mM NaCO3, pH 9.5). The strips were blocked overnight with 2%
w/v BSA at 4 °C and cut into 4 cm × 0.5 cm segments before use. An
amount of 7.5 μL of protein−AuNP conjugate samples at OD525nm =
10 was mixed with 7.5 μL of antigen solution and incubated for 5 min
before applying to the opposite end of the nitrocellulose strip to the
antibody lines. The solution progressed through the membrane via
capillary action and the strips were washed 5 times with 20 μL of
washing buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20,
pH 7.8) before imaging with a digital camera.
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■ ABBREVIATIONS
AuNP = gold nanoparticle
LSPR = localized surface plasmon resonance
DLS = dynamic light scattering
AUC = analytical ultracentrifugation
OD = optical density
TEM = transmission electron microscopy
mAb = monoclonal antibody
OmpATM = transmembrane domain of E. coli outer
membrane protein A
cysOmpATM = cysteine mutant of OmpATM
GGzOmpATM = N terminal tandem pair of B domains from
protein G and Z domain from protein A fused to a
cysOmpATM scaffold
scFvOmpATM = N-terminal single chain variable fragment
domain fused to an *OmpATM scaffold
*OmpATM = α helical linker domain fused to cysOmpATM
FluA NP = influenza A nucleoprotein
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